All data are based on the daily closing price as of September 15, 2025
g

GNI Group

2160.TSE
17.48 USD
-0.10
-0.57%

Overview

Last close
17.48 usd
Market cap
971.06M usd
52 week high
30.23 usd
52 week low
10.22 usd
Target price
29.18 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
5.9515
Price/Book Value
4.0718
Enterprise Value
888.21M usd
EV/Revenue
5.4235
EV/EBITDA
318.9585

Key financials

Revenue TTM
163.77M usd
Gross Profit TTM
117.44M usd
EBITDA TTM
-1.88M usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
470.00M usd
Net debt
-39.30M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
  • Symbol
    2160.TSE
  • Exchange
    TSE
  • Isin
    JP3386370005
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Ying Luo Ph.D.
  • Headquarter
    Tokyo
  • Web site
    https://www.gnipharma.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top